Skip to content

Study · Non-randomized trial · n = 34 · 1990

6 results

Fast and effective treatment of malignant hypercalcemia. Combination of suppositories of calcitonin and a single infusion of 3-amino 1-hydroxypropylidene-1-bisphosphonate.

Thiébaud D, Jacquet AF, Burckhardt P

Archives of internal medicine1 Oct 1990Cited by 14 (Europe PMC)

PMID2222097 (opens in a new tab)DOI10.1001/archinte.1990.00390210095021 (opens in a new tab)PepBankPUB-02222097
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In malignant hypercalcemia, added salmon calcitonin was linked to plasma calcium normalization within 9 days in all 17 patients versus 14 of 17 with APD alone.

    In plain wordsIn malignant hypercalcemia, added salmon calcitonin was linked to more patients reaching normal calcium than APD alone.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreasePlasma calcium normalization
    Study

    n = 34

    Comparator
    APD alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · suppositories · 3 daysAs given in this study (human).

    Measurements

    Patients with normalization
    17 patients
    calcitonin plus APD
    Patients with normalization
    14 patients
    APD alone
    Time to normalization
    ≤ 9 days
    calcitonin plus APD
    Initial plasma calcium
    3.22 mmol/L
    calcitonin plus APD
    Final plasma calcium
    2.29 mmol/L
    calcitonin plus APD

    Source sentences

    Summary
    All patients receiving the combination of calcitonin and APD achieved normalization of the plasma calcium level within 9 days, with a decrease from 3.22 +/- 0.90 mmol/L (mean +/- SEM) to 2.29 +/- 0.03 mmol/L.
    3 context sentences
    Summary · context
    In the group receiving APD alone, the plasma calcium level normalized in only 14 of 17 patients by day 9.
    Summary · context
    Seventeen patients with malignant hypercalcemia were treated with a combination of a single dose of 3-amino 1-hydroxypropylidene-1-bisphosphonate (APD [also known as AHPrBP or palmidronate disodium]) and salmon calcitonin given as suppositories for 3 days.
    Summary · context
    To assess whether such a combined short treatment has a significant benefit leading to earlier normalization of the plasma calcium level than does APD alone, 17 additional patients matched for the type of tumor, initial plasma calcium level, urinary hydroxyproline level, and the dose of APD served as controls.
  2. 02HumanNon-randomized trialEfficacy outcome

    In malignant hypercalcemia, added salmon calcitonin was linked to faster calcium decline and lower calcium on days 2 to 4 than APD alone.

    In plain wordsIn malignant hypercalcemia, added salmon calcitonin was linked to faster calcium reduction than APD alone.

    Peptide
    Calcitonin-salmon
    Outcome
    IncreaseSpeed of plasma calcium decline
    Study

    n = 34

    Comparator
    APD alone
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · suppositories · 3 daysAs given in this study (human).

    Source sentences

    Summary
    In the group receiving calcitonin and APD, the drop in the plasma calcium level occurred more rapidly, and the plasma calcium values were lower from days 2 to 4.
    2 context sentences
    Summary · context
    Seventeen patients with malignant hypercalcemia were treated with a combination of a single dose of 3-amino 1-hydroxypropylidene-1-bisphosphonate (APD [also known as AHPrBP or palmidronate disodium]) and salmon calcitonin given as suppositories for 3 days.
    Summary · context
    To assess whether such a combined short treatment has a significant benefit leading to earlier normalization of the plasma calcium level than does APD alone, 17 additional patients matched for the type of tumor, initial plasma calcium level, urinary hydroxyproline level, and the dose of APD served as controls.
  3. 03HumanNon-randomized trialEfficacy outcome

    In malignant hypercalcemia, added calcitonin was linked to a lower renal calcium reabsorption setting than APD alone: 2.16 versus 2.34 mmol/L.

    In plain wordsIn malignant hypercalcemia, added calcitonin was linked to a lower renal calcium reabsorption setting than APD alone.

    Peptide
    Calcitonin-salmon
    Outcome
    DecreaseRenal calcium reabsorption setting
    Study

    n = 34

    Comparator
    APD alone
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · suppositories · 3 daysAs given in this study (human).

    Measurements

    Renal reabsorption setting
    2.16 mmol/L
    calcitonin plus APD
    SEM
    0.06 mmol/L
    calcitonin plus APD
    Renal reabsorption setting
    2.34 mmol/L
    APD alone
    SEM
    0.06 mmol/L
    APD alone

    Source sentences

    Summary
    This advantage was explained by the calciuric effect of calcitonin, as reflected by a significant decrease in the notional setting of renal reabsorption of calcium, reaching 2.16 +/- 0.06 mmol/L compared with 2.34 +/- 0.06 mmol/L in the group receiving APD alone.
    2 context sentences
    Summary · context
    Seventeen patients with malignant hypercalcemia were treated with a combination of a single dose of 3-amino 1-hydroxypropylidene-1-bisphosphonate (APD [also known as AHPrBP or palmidronate disodium]) and salmon calcitonin given as suppositories for 3 days.
    Summary · context
    To assess whether such a combined short treatment has a significant benefit leading to earlier normalization of the plasma calcium level than does APD alone, 17 additional patients matched for the type of tumor, initial plasma calcium level, urinary hydroxyproline level, and the dose of APD served as controls.
  4. 04HumanNon-randomized trialSafety outcome

    In malignant hypercalcemia, no side effects occurred with salmon calcitonin plus APD or APD alone.

    In plain wordsNo side effects occurred with salmon calcitonin plus APD or APD alone.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableSide effects
    Study

    n = 34

    Comparator
    APD alone
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · suppositories · 3 daysAs given in this study (human).

    Source sentences

    Summary
    There were no side effects of both treatments, in particular neither flushing nor nausea induced by the suppositories of calcitonin.
    2 context sentences
    Summary · context
    Seventeen patients with malignant hypercalcemia were treated with a combination of a single dose of 3-amino 1-hydroxypropylidene-1-bisphosphonate (APD [also known as AHPrBP or palmidronate disodium]) and salmon calcitonin given as suppositories for 3 days.
    Summary · context
    To assess whether such a combined short treatment has a significant benefit leading to earlier normalization of the plasma calcium level than does APD alone, 17 additional patients matched for the type of tumor, initial plasma calcium level, urinary hydroxyproline level, and the dose of APD served as controls.
  5. 05HumanNon-randomized trialSafety outcome

    In patients with malignant hypercalcemia, neither salmon calcitonin plus APD nor APD alone caused flushing.

    In plain wordsIn patients with malignant hypercalcemia, neither salmon calcitonin plus APD nor APD alone caused flushing.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableFlushing
    Study

    n = 34

    Comparator
    APD alone
    Outcome group
    Adverse events · Skin and wound
    Studied dose
    Dose not stated · suppositories · 3 daysAs given in this study (human).

    Source sentences

    Summary
    There were no side effects of both treatments, in particular neither flushing nor nausea induced by the suppositories of calcitonin.
    2 context sentences
    Summary · context
    Seventeen patients with malignant hypercalcemia were treated with a combination of a single dose of 3-amino 1-hydroxypropylidene-1-bisphosphonate (APD [also known as AHPrBP or palmidronate disodium]) and salmon calcitonin given as suppositories for 3 days.
    Summary · context
    To assess whether such a combined short treatment has a significant benefit leading to earlier normalization of the plasma calcium level than does APD alone, 17 additional patients matched for the type of tumor, initial plasma calcium level, urinary hydroxyproline level, and the dose of APD served as controls.
  6. 06HumanNon-randomized trialSafety outcome

    In patients with malignant hypercalcemia, neither salmon calcitonin plus APD nor APD alone caused nausea.

    In plain wordsIn patients with malignant hypercalcemia, neither salmon calcitonin plus APD nor APD alone caused nausea.

    Peptide
    Calcitonin-salmon
    Outcome
    Not applicableNausea
    Study

    n = 34

    Comparator
    APD alone
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated · suppositories · 3 daysAs given in this study (human).

    Source sentences

    Summary
    There were no side effects of both treatments, in particular neither flushing nor nausea induced by the suppositories of calcitonin.
    2 context sentences
    Summary · context
    Seventeen patients with malignant hypercalcemia were treated with a combination of a single dose of 3-amino 1-hydroxypropylidene-1-bisphosphonate (APD [also known as AHPrBP or palmidronate disodium]) and salmon calcitonin given as suppositories for 3 days.
    Summary · context
    To assess whether such a combined short treatment has a significant benefit leading to earlier normalization of the plasma calcium level than does APD alone, 17 additional patients matched for the type of tumor, initial plasma calcium level, urinary hydroxyproline level, and the dose of APD served as controls.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.